Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
COYA Stock Forecast 2026-2027
$4.86
Current Price
$113.88M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to COYA Price Targets
+270.8%
To High Target of $18.00
+219.3%
To Median Target of $15.50
+147.2%
To Low Target of $12.00
COYA Price Momentum
-15.5%
1 Week Change
+2.5%
1 Month Change
-21.1%
1 Year Change
-16.2%
Year-to-Date Change
-37.4%
From 52W High of $7.75
+30.9%
From 52W Low of $3.71
📊 TOP ANALYST CALLS
Did COYA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Coya is one of their latest high-conviction picks.
Latest COYA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, COYA has a bullish consensus with a median price target of $15.50 (ranging from $12.00 to $18.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $4.86, the median forecast implies a 219.3% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Boobalan Pachaiyappan at Roth Capital, suggesting a 147.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COYA Analyst Ratings
6
Buy
0
Hold
0
Sell
COYA Price Target Range
Low
$12.00
Average
$15.50
High
$18.00
Current: $4.86
Latest COYA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COYA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 12, 2026 | Chardan Capital | Keay Nakae | Buy | Maintains | $14.00 |
| Jun 5, 2026 | Roth Capital | Boobalan Pachaiyappan | Buy | Initiates | $12.00 |
| Apr 10, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 19, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 16, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 16, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Feb 18, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Feb 2, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 21, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 8, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Jan 8, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 5, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 23, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 9, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 14, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 13, 2025 | BTIG | Buy | Maintains | $N/A | |
| Nov 12, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 30, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Sep 29, 2025 | D. Boral Capital | Buy | Maintains | $N/A |
Coya Therapeutics Inc. (COYA) Competitors
The following stocks are similar to Coya based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Coya Therapeutics Inc. (COYA) Financial Data
Coya Therapeutics Inc. has a market capitalization of $113.88M with a P/E ratio of -3.8x. The company generates $7.94M in trailing twelve-month revenue with a -266.1% profit margin.
Revenue growth is -2.6% quarter-over-quarter, while maintaining an operating margin of -3,038.1% and return on equity of -51.3%.
Valuation Metrics
Market Cap
$113.88M
Enterprise Value
$72.66M
P/E Ratio
-3.8x
PEG Ratio
0.1x
Price/Sales
15.5x
Growth & Margins
Revenue Growth (YoY)
-2.6%
Gross Margin
N/A
Operating Margin
-3,038.1%
Net Margin
-266.1%
EPS Growth
-2.6%
Financial Health
Cash/Price Ratio
+44.5%
Current Ratio
15.0x
Debt/Equity
0.0x
ROE
-51.3%
ROA
-27.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Coya Therapeutics Inc. (COYA) Business Model
About Coya Therapeutics Inc.
What They Do
Develops regenerative medicines for neurodegenerative diseases.
Business Model
Coya Therapeutics Inc. operates by focusing on the research and development of innovative therapies that utilize immunotherapy and stem cell technology. The company aims to generate revenue through partnerships, grants, and potentially commercialization of its treatments targeting conditions like ALS.
Additional Information
Coya Therapeutics is recognized for its unique approach in using regulatory T-cells to modulate the immune system, positioning it as a significant player in the biopharmaceutical industry. The company's work addresses critical unmet medical needs, potentially transforming patient care in challenging medical conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
8
CEO
Dr. Arun Swaminathan Ph.D.
Country
United States
IPO Year
2022
Website
www.coyatherapeutics.comCoya Therapeutics Inc. (COYA) Latest News & Analysis
Latest News
Quick Summary
Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) performance has been compared to their sector's performance year-to-date. Further details on metrics were not provided.
Why It Matters
Performance comparisons highlight Coya Therapeutics' and Quest Diagnostics' market standing, influencing investor sentiment and potential investment decisions in biotech and diagnostics sectors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Coya Therapeutics will present its ALSTARS trial focused on neuroinflammation at the ENCALS Meeting 2026 in Madrid, scheduled for June 24-26, 2026.
Why It Matters
Coya Therapeutics' presentation on the ALSTARS trial could signal advancements in treating neurodegenerative disorders, potentially boosting investor confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Coya Therapeutics, Inc. (NASDAQ: COYA) will host a webinar on June 24, 2026, discussing the link between repetitive head trauma, inflammation, and neurodegenerative diseases.
Why It Matters
Coya Therapeutics' webinar on neurodegenerative disorders may signal advancements in their research, potentially impacting stock performance and investor interest in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Coya Therapeutics (NASDAQ: COYA) has started the blinded extension phase of its ALSTARS Trial, allowing patients from the initial 24-week phase to continue their treatment regimen.
Why It Matters
Coya Therapeutics' advancement in the ALSTARS Trial signals progress in developing Treg-enhancing biologics, potentially impacting future revenue and market position, which can influence stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit
1 month ago
Quick Summary
Coya Therapeutics will present its ALSTARS trial on neuroinflammation targeting at the ALS Drug Development Summit, June 2-4, 2026, in Boston, MA.
Why It Matters
Coya's presentation on the ALSTARS trial could highlight advancements in neurodegenerative treatments, potentially boosting investor confidence and impacting stock performance in biotech.
Source: Business Wire
Market Sentiment:
Neutral
Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2 months ago
Quick Summary
Coya Therapeutics (NASDAQ: COYA) reported Q1 2026 financial results, highlighting progress in developing T-cell biologics for neurodegenerative disorders and a strong start to the year.
Why It Matters
Coya Therapeutics' strong Q1 results and ongoing clinical progress may signal potential growth and innovation in the biotech sector, influencing stock performance and investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About COYA Stock
What is Coya Therapeutics Inc.'s (COYA) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Coya Therapeutics Inc. (COYA) has a median price target of $15.50. The highest price target is $18.00 and the lowest is $12.00.
Is COYA stock a good investment in 2027?
According to current analyst ratings, COYA has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COYA stock?
Wall Street analysts predict COYA stock could reach $15.50 in the next 12 months. This represents a 219.3% increase from the current price of $4.86. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Coya Therapeutics Inc.'s business model?
Coya Therapeutics Inc. operates by focusing on the research and development of innovative therapies that utilize immunotherapy and stem cell technology. The company aims to generate revenue through partnerships, grants, and potentially commercialization of its treatments targeting conditions like ALS.
What is the highest forecasted price for COYA Coya Therapeutics Inc.?
The highest price target for COYA is $18.00 from at , which represents a 270.8% increase from the current price of $4.86.
What is the lowest forecasted price for COYA Coya Therapeutics Inc.?
The lowest price target for COYA is $12.00 from Boobalan Pachaiyappan at Roth Capital, which represents a 147.2% increase from the current price of $4.86.
What is the overall COYA consensus from analysts for Coya Therapeutics Inc.?
The overall analyst consensus for COYA is bullish. Out of 3 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.50.
How accurate are COYA stock price projections?
Stock price projections, including those for Coya Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 7:16 AM UTC